FEC Mobilized Stem Cells for High-dose Therapy in Breast Cancer Patients

REFERENCES

• Antman K, Rowlings P, Vaughan W, et al. High-dose chemotherapy with autologous hematopoietic stem-cell sup-port for breast cancer in North America. J Clin Oncol 1997; 15: 1870–9.
   PubMed Web of Science ®Google Scholar
• Elias A, Ayash L, Anderson K, et al. Mobilization of periph-eral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036–44.
   PubMed Web of Science ®Google Scholar
• Gianni A, Gregni M, Siena S, et al. Rapid and complete hemopoietic reconstitution following combined transplanta-tion of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy? Hematol Oncol 1989; 7: 139–48.
   Google Scholar
• Jones H, Jones S, Watts M, et al. Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. J Clin Oncol 1994; 12: 1693–702.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Linch D, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell trans-plantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–7.
   PubMed Web of Science ®Google Scholar
• Peters W, Shpall E, Jones R, et al. High-dose combination alkylating agents with bone marrow support as initial treat-ment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368 —76.
   PubMedGoogle Scholar
• Dunphy F, Spitzer G, Buzdar A, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone mar-row support. J Clin Oncol 1990; 8: 1207–16.
   PubMed Web of Science ®Google Scholar
• Kennedy M, Beveridge R, Rowley S, Gordon G, Abeloff M, Davidson N. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense in-duction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 920–6.
   PubMed Web of Science ®Google Scholar
• Williams S, Gilewski T, Mick R, Bitran J. High-dose consoli-dation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743–7.
   PubMed Web of Science ®Google Scholar
• Antman K, Souhami R. High-dose chemotherapy in solid tumours. Annals Oncol 1993; 4: 29–44.
   PubMed Web of Science ®Google Scholar
• Ayash L, Elias A, Wheeler C, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibil-ity study. J Clin Oncol 1994; 12: 37–44.
   PubMed Web of Science ®Google Scholar
• Leonard R. High-dose chemotherapy for breast cancer. Eur J Cancer 1996; 32A: 205–8.
   PubMedGoogle Scholar
• Bezwoda W, Seymour L, Dansey R. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483–9.
   Google Scholar
• Gianni A, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; II: 580–5.
   Google Scholar
• Gianni A, Bregni M, Siena S, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990; 8: 768–78.
   PubMed Web of Science ®Google Scholar
• Bregni M, Siena S, Di Nicola M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor and granu-locyte colony-stimulating factor after high-dose cyclophos-phamide cancer therapy. J Clin Oncol 1996; 14: 628–35.
   PubMedGoogle Scholar
• Kotasek D, Shepherd K, Sage R, et al. Factors affecting blood stem cell collections following high-dose cyclophos-phamide mobilization in lymphoma, myeloma and solid tu-mors. Bone Marrow Transpl 1992; 9: 11–7.
   PubMed Web of Science ®Google Scholar
• Sheridan W, Begley C, Juttner C, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640–4.
   PubMed Web of Science ®Google Scholar
• Eder J, Elias A, Shea T, et al. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 1990; 8: 1239–45.
   PubMed Web of Science ®Google Scholar
• Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable ad-vanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102–10.
   PubMed Web of Science ®Google Scholar
• Bergh J, Wiklund T, Erikstein B, et al. Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity to high-risk breast can-cer patients. Ann Oncol 1998; 9: 403–11.
   PubMed Web of Science ®Google Scholar
• Schwartzberg L, Birch R, Blanco R, et al. Rapid and sus-tained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transpl 1993; 11: 369–74.
   PubMed Web of Science ®Google Scholar
• Colton T. Statistics in medicine. Boston: Little, Brown, 1974.
   Google Scholar
• Brugger W, Bross K, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic pro-genitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636–40.
   PubMed Web of Science ®Google Scholar
• EBCTCG. Systemic treatment of early breast cancer by hor-monal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15, 71–85.
   PubMedGoogle Scholar
• Rowlings P, Bayly J, Rawling C, Juttner C, To L. A compari-son of peripheral blood stem cell mobilisation after chemotherapy with cyclophosphamide as a single agent in doses of 4 g/m2 or 7 g/m2 in patients with advanced cancer. Aust NZ J Med 1992; 22: 660–4.
   Google Scholar
• Rosenfeld C, Shadduck R, Zeigler Z, Andrews F, Nemunaitis J. Cyclophosphamide-mobilized peripheral blood stem cells in patient with lymphoid malignancies. Bone Marrow Transpl 1995; 15: 433–8.
   Google Scholar
• Watts M, Sullivan A, Jamieson E, et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulo-cyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parame-ters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535–46.
   PubMed Web of Science ®Google Scholar
• Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–94.
   PubMed Web of Science ®Google Scholar
• Zimmerman T, Lee W, Bender J, Mick R, Williams S, et al. Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvests. Bone Marrow Transpl 1995; 15: 439–44.
   PubMedGoogle Scholar